This Q&A with Dana Farber’s Dr. Rinath Jeselsohn centers on fulvestrant (Faslodex, AZ) and its current role in the management of breast cancer, as well as outlining the emerging selective estrogen receptor degraders (SERDs), their clinical trial data, potential for use, and whether the options will become the “backbone” of endocrine therapy in HER2-negative metastatic […]
MedPage Today presents this illuminating conversation with Daniel Gibbs, MD, PhD, a retired neurologist and author of the book, A Tattoo on my Brain: A Neurologist’s Personal Battle against Alzheimer’s Disease. In the question-and-answer session, Dr. Gibbs discusses his early diagnosis, his participation in clinical trials, and his experiences and unique perspectives as a neurologist […]
In this interview with Dr. Richard Furman, Professor of Medicine at New York-Presbyterian Weill Cornell Medicine, the importance of the CLL14 study is highlighted. In addition, Dr. Furman discusses the best use of venetoclax and whether anti-CD20 agents really add to the benefit of venetoclax treatment and whether a policy of watch and wait is […]
In this Q&A with Dr. Jorge Cortes, the Director of the Georgia Cancer Center, the drug asciminib is discussed based on its utility as a third-generation TKI as well as its favorable, unique characteristics. Early data has shown promising results with few adverse events, possibly illuminating the drug as a potential first-in-class agent.
From the pages of Clinical Advances in Hematology & Oncology comes this Q&A with Jennifer A. Woyach, MD, a Professor of Medicine in the Division of Hematology at the Ohio State University Comprehensive Cancer Center. Dr. Woyach provides extensive commentary on BTK, BCL2, and PI3K inhibitors, FCR usage, and the importance of clinical trials when […]
In June 2020, the US Food and Drug Administration (FDA) granted accelerated approval to tazemetostat (Tazverik, Epizyme), an oral EZH2 inhibitor for the treatment of adult patients with relapsed/refractory follicular lymphoma (FL). Clinical Advances in Hematology & Oncology takes a closer look at this new treatment through a conversation with Dr. Connie Lee Batlevi from […]
In this Q&A, Dr. Gautam Borthakur from the University of Texas MD Anderson Cancer Center talks with Clinical Advances in Hematology & Oncology about the goals, treatment options (including tailored treatment), differences in de novo vs. therapy-related, and other suggestions in patients with core-binding factor acute myeloid leukemia (AML).
ASH Clinical News speaks with Maureen Achebe, MD, MPH, Clinical Director of the Non-Malignant Hematology Clinic at Brigham and Women’s Hospital in Boston, and other experts, about the safety and efficacy of IV iron products, how they are perceived in the community, and barriers to their use in the clinic.
Anthony Fauci, MD, director of the National Institutes of Allergy and Infectious Diseases (NIAID), joined Lungcast, a respiratory health podcast series from HCPLive and the American Lung Association (ALA), to discuss the CDC’s varying take on SARS-CoV-2 transmission and testing parameters. Fauci also shared suggestions for college campus to mitigate community-based spread while classes continue.
In this podcast, Dr. Jennifer Caudle speaks with Drs. Kathryn Ruddy and Joerg Herrmann from the cardio-oncology clinic at the Mayo Clinic to talk about the field that’s devoted to improving cardiovascular health both during and after cancer therapy.